ThromboGenics: Clinical Trials

19 trials sponsored by ThromboGenics, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

13 completed, 5 terminated, 1 unknown. 19 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 219Completed 13, Terminated 5, Unknown 1

Follow ThromboGenics: new trials by email

Trials (filtered) newest first · largest first

All 19 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Treatment of Post-Ocriplasmin Therapy Vitreolysis Induced Subretinal Fluid With Eplerenone (Mineralocorticoid Antagonists)
Eplerenone - Vitreomacular Traction, Subretinal Edema
Phase 2TerminatedWagner Macula & Retina Center22019-10-042021-01-08
A Study to Evaluate THR-317 Treatment for Macular Telangiectasia Type 1 (MacTel 1)
THR-317 8mg - Retinal Telangiectasis, Idiopathic Juxtafoveal Retinal Telangiectasia
Phase 2CompletedThromboGenics82018-09-182020-09-02
A Study to Evaluate the Safety and Efficacy of THR-317 for the Treatment of Diabetic Macular Oedema (DME)
Anti-PlGF recombinant monoclonal antibody, 4mg dose, Anti-PlGF recombinant monoclonal antibody, 8mg dose - Diabetic Retinopathy, Macular Edema
Phase 2CompletedThromboGenics492016-12-222018-04-17
A Study to Evaluate the Efficacy and Safety of Ocriplasmin in Inducing Total PVD in Subjects With NPDR
ocriplasmin 0.0625mg, ocriplasmin 0.125mg, Sham injection - Diabetic Retinopathy, Posterior Vitreous Detachment
Phase 2TerminatedThromboGenics482015-12-012020-12-16
Single IV Administration of TB-402 for Prophylaxis of Venous Thromboembolic Events (VTE) After Total Hip Replacement Surgery
TB-402, Rivaroxaban - Prophylaxis of Venous Thromboembolic Events
Phase 2CompletedThromboGenics6322011-04-012012-08-23
The Purpose of This Study is to Evaluate the Pharmacokinetic Properties of Intravitreal Ocriplasmin Prior to Planned Primary Pars Plana Vitrectomy (PPV)
ocriplasmin - Vitrectomy
Phase 2CompletedThromboGenics382010-07-012014-12-17
Clinical Trial of Intravitreal Microplasmin in Infants and Children Scheduled for Vitrectomy
Ocriplasmin, Placebo - Vitrectomy
Phase 2CompletedThromboGenics242010-02-012014-12-17
Safety and Efficacy Study of Intravitreal Ocriplasmin in Subjects With AMD With Focal Vitreomacular Adhesion
Ocriplasmin, Sham injection - Exudative Age-Related Macular Degeneration, Focal Vitreomacular Adhesion
Phase 2CompletedThromboGenics1002010-01-012014-12-17
Safety and Efficacy Study of Microplasmin in for Non-Surgical Treatment of Focal Vitreomacular Adhesion
Microplasmin - Focal Vitreomacular Adhesion
Phase 2CompletedThromboGenics172010-01-012014-04-07
Study of Intravitreal Microplasmin in Relieving Vitreo-Macular Adhesion in Neovascular Age-related Macular Degeneration
Microplasmin, Placebo control - Macular Degeneration
Phase 2UnknownUniversity of California, Los Angeles302009-10-012011-09-27
Single Intravenous Administration of TB-402 for the Prophylaxis of Venous Thromboembolic Events (VTE) After Total Knee Replacement Surgery
TB-402, Enoxaparin - Total Knee Replacement Surgery
Phase 2CompletedThromboGenics3162008-12-012014-04-07
Microplasmin Administered Via the Trellis-8 Infusion System for Treatment of Acute Iliofemoral DVT
microplasmin - Deep Vein Thrombosis
Phase 2TerminatedThromboGenics62007-03-012014-04-07
A Study to Compare Multiple Doses Intravitreal Microplasmin for Treatment of Patients With Vitreomacular Traction (MIVI-IIt)
ocriplasmin, Sham Comparator - Vitreomacular Traction
Phase 2CompletedThromboGenics602007-02-012014-12-17
A Multicenter Study to Compare Multiple Doses of Intravitreal Microplasmin Versus Sham Injection for Treatment of Patients With Diabetic Macular Edema (DME)
ocriplasmin, Sham injection - Diabetic Macular Edema
Phase 2CompletedThromboGenics512006-12-012014-12-17
A Study of the Safety and Efficacy of Microplasmin to Induce a Posterior Vitreous Detachment (MIVI III)
Ocriplasmin 25µg, Ocriplasmin 75µg, Ocriplasmin 125µg - Vitrectomy
Phase 2CompletedThromboGenics1252006-12-012014-12-17
Intra-arterial Microplasmin Administration in Patients With Acute Intracranial Vertebrobasilar Artery Occlusion
Microplasmin - Stroke
Phase 2TerminatedThromboGenics22006-12-012014-04-07
Intravenous Administration of Microplasmin for Treatment of Acute Ischemic Stroke
Microplasmin - Stroke, Acute
Phase 2CompletedThromboGenics402005-10-012014-11-07
Intra-arterial Microplasmin Administration in Patients With Acute Peripheral Arterial Occlusion
Microplasmin - Arterial Occlusive Diseases
Phase 2TerminatedThromboGenics192005-03-012014-04-07
Intravitreal Microplasmin in Patients Undergoing Surgical Vitrectomy
Microplasmin - Vitreomacular Traction Maculopathy, Eye Diseases
Phase 2CompletedThromboGenics602004-12-012014-04-07

Conditions studied

Diabetic Retinopathy (3)  ·  Macular Degeneration (2)  ·  Stroke (2)  ·  Arterial Occlusive Diseases (1)  ·  Disease Progression (1)  ·  Eye Diseases (1)  ·  Idiopathic Juxtafoveal Retinal Telangiectasia (1)  ·  Ischemic Stroke (1)  ·  Macular Edema (1)  ·  Retinal Perforations (1)  ·  Retinal Telangiectasis (1)  ·  Thromboembolism (1)  ·  Venous Thrombosis (1)  ·  Vitreous Detachment (1)

Interventions

microplasmin (14)  ·  salicylhydroxamic acid (3)  ·  TB 402 (2)  ·  Enoxaparin (1)  ·  Eplerenone (1)  ·  Rivaroxaban (1)  ·  TB-403 (1)

Countries

Belgium (9)  ·  Germany (6)  ·  United States (6)  ·  Netherlands (4)  ·  France (3)  ·  Hungary (3)  ·  Italy (3)  ·  United Kingdom (3)  ·  Austria (2)  ·  Bulgaria (2)  ·  Czechia (2)  ·  Israel (2)  ·  Latvia (2)  ·  Poland (2)  ·  Russia (2)

Top investigators

Gerard O'Sullivan, MD (1)  ·  Gerhard Hamann, Prof. Dr (1)  ·  Peter Verhamme, MD, PhD (1)  ·  Steven D Schwartz, M.D. (1)  ·  Vincent Thijs, MD PhD (1)

Results publications

PMID 23982845

NIH funding

2015 (1), 2016 (1), 2017 (1)